de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

By Maggie Fick LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely ...

Add Yahoo as a preferred source to see more of our stories on Google. The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a ...

This deal comes as the total value of AI partnerships takes a 120% uptick year-on-year between 2024 and 2025, as per ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early ...

Novo Nordisk on Tuesday announced a partnership with OpenAI to deploy artificial intelligence across its business, spanning ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

In this Q&A, Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discusses how earlier, human-relevant data is reshaping go ...

Although the past decade has been marked by lack of innovation in the field of antibiotics development, that trend is changing, according to data from Reportlinker. According to the data, 109 ...

DENVER The last time a new tuberculosis drug was developed, Richard Nixon was in the White House. That drug, Rifampin, "was the biggest thing to hit TB in 30 years," said Dr. Michael Iseman, a ...